Patricia Kindsvater, MD
Family Medicine · East China, MINPI 1508398405
Payments from drug & device makers
Across 93 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$266
- Teva Pharmaceuticals USA, Inc.$161
- Amgen$141
- QOL Medical, LLC$99
- Novartis$87
- Novo Nordisk$74
- plus $530 from 19 others
What the payments were for
- Food & beverage$1,33899%
- Other$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $266 |
| Teva Pharmaceuticals USA, Inc. | 9 | $161 |
| Amgen | 8 | $141 |
| QOL Medical, LLC | 7 | $99 |
| Novartis | 5 | $87 |
| Novo Nordisk | 5 | $74 |
| Amarin Pharma, Inc. | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Boehringer Ingelheim | 3 | $55 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| GSK | 3 | $41 |
| UCB, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Lilly USA, LLC | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Pfizer | 1 | $17 |
| Merck | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
How this compares
$1,359 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $76,768 |
| MounjaroTirzepatide | 32 | $45,140 |
| JardianceEmpagliflozin | 22 | $36,755 |
| TrulicityDulaglutide | 25 | $24,110 |
| OzempicSemaglutide | 15 | $20,098 |
| BriviactBrivaracetam | 24 | $18,145 |
| XareltoRivaroxaban | 11 | $16,678 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $11,634 |
| LinzessLinaclotide | 12 | $10,519 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $7,661 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $6,614 |
| Atorvastatin Calcium | 474 | $6,364 |
| PaxlovidNirmatrelvir/Ritonavir | 22 | $5,296 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,772 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $4,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $17 | $82,06483 claims |
| Lilly USA, LLCMounjaro, Trulicity | $27 | $69,25057 claims |
| Boehringer IngelheimJardiance | $55 | $36,75522 claims |
| Novo NordiskOzempic | $74 | $20,09815 claims |
| UCB, Inc.Briviact | $28 | $18,14524 claims |
| AbbVieLinzess, Synthroid | $266 | $12,44137 claims |
| GSKTrelegy Ellipta | $41 | $11,63413 claims |
| AstraZenecaSymbicort | $14 | $4,77215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in East China
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.